Best Healthcare Companies in Shenzhen, China
The 91 best Healthcare companies in Shenzhen, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DistinctClinic.
Ranked: Best Healthcare companies in Shenzhen
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DistinctClinic Chain of general clinics | $168M | 57 mo ago | 36 | — | Node.jsKongNginx+4 | Top 10M | — | 2 partnerships · 1 expansion |
| 2 | Xbiome Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome 64AI top 20%Funding top 36%Moat top 38%Market top 49% All 5 signals ▾AItop 20% Fundingtop 36% Moattop 38% Markettop 49% Globalbottom 36% AI: Classified as an AI company Funding: Raised $108M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $108M | 54 mo ago | 63 | — | — | — | — | — |
| 3 | HwaGen Pharma CDMO focused on manufacturing of APIs | $100M | 58 mo ago | 500 | — | — | — | — | — |
| 4 | Yimai Sunshine Imaging Hospital Group Operator of medical imaging centers providing diagnostic and related healthcare services | $83M | 83 mo ago | 970 | — | PHPNginxSwiper+2 | Top 50M | — | — |
| 5 | Readline R&D company manufacturing and exporting cosmetic, drug, and amino acid peptides | $74M | 15 mo ago | 300 | Jian Liu Co-Founder | jQuerySlickBaidu Analytics (百度统计) | Top 50M | — | — |
| 6 | Ruiguang Kangtai Technology Manufacturer of blood pressure measurement and laser therapy devices | $56M | 69 mo ago | — | — | Apache HTTP ServerAOSSwiper+1 | Top 50M | — | — |
| 7 | Global Pharm Holdings Developer and manufacturer of herbal medicines | $47M | 175 mo ago | 500 | Yunlu Yin Chairman & CEO | — | — | — | — |
| 8 | Shankang Medical R&D based manufacturer of drugs for multiple therapeutics | $28M | 57 mo ago | 127 | — | — | — | — | — |
| 9 | Belter Devices for personal health monitoring | $18M | 139 mo ago | — | — | — | — | — | — |
| 10 | Shenzhen Qianhai Xiaozao Technology Offers microbial expression systems-based biologics development and manufacturing services | $16M | 61 mo ago | 130 | — | — | — | — | 1 launch |
| 11 | Shenzhen Weigong Technology Manufacturer of flow cytometer, sampling tray, lysing, and other lab tools | $15M | 59 mo ago | — | Li Weigong Founder | — | — | — | — |
| 12 | Hybio Pharmaceutical Developer and manufacturer of polypeptide drugs and APis | $15M | 219 mo ago | 975 | Jiancheng Yuan CEO & President | NginxGoogle Font APIAOS+4 | Top 10M | 192 patents Polypeptide drug synthesis, purification, formulation, and antiviral peptide development. | — |
| 13 | Quiknos Solution for laboratory test management | $15M | 95 mo ago | — | Charles Wang Co-Founder | — | — | — | — |
| 14 | PAM²L Biotechnologies Supplier and wholesaler of bio-pharmaceutical products | $15M | 41 mo ago | — | Zhong Chao Founder | — | — | — | — |
| 15 | Sailu Medical Provider of upstream sequencing platforms development services | $14M | 44 mo ago | — | — | — | — | — | — |
| 16 | Shenzhen Yihe Health Management Standalone gynecology clinic | $7M | 57 mo ago | — | Pei Honggang Founder | — | — | — | — |
| 17 | Hochuen Medical Manufacturer of medical disposables & devices, and wearable medical products | $6M | 40 mo ago | 19 | Robin Liu Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+15 | Top 50M | — | — |
| 18 | APK Technology Manufacturer of medical cables, sensors, and related consumables | $3M | 159 mo ago | — | Rao Xiaomao CEO | Node.jsPHPElement UI+8 | Top 10M | — | 1 partnership |
| 19 | Shenzhen Boen Clinical Standalone general clinic | $1M | 86 mo ago | 60 | — | — | — | — | — |
| 20 | Medcaptain Manufacturer of medical devices including patient monitoring and diagnostic equipment | $206K | 76 mo ago | 126 | Jie Liu Co-Founder & CEO | JavaVue.jsTengine+5 | Top 5M | — | 2 launchs |
Top 12 Healthcare companies in Shenzhen
#1
Series C · Shenzhen, Guangdong Province · founded 2013 · 300 employees$74.3Mraised▾
R&D company manufacturing and exporting cosmetic, drug, and amino acid peptides
- Feb 2025Series C$68.9M
- Dec 2022Series B$43M
- Nov 2021Series A$31.3M
#2
Public · Shenzhen, Guangdong Province · founded 2012 · 36 employees$167.5Mraised▾
Chain of general clinics
- Sep 2021Series E$60M
- 2019Series D$50M
- Aug 2017Series C$40M
- Apr 2015Series B$17.5M
#3
Series B · Shenzhen, Guangdong Province · founded 2017 · 63 employees$107.5Mraised▾
Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome. The company uses Fecal microbiota transplantation (FMT) technology for the development of drugs for multiple diseases. It includes extraction of microbiota from the stool of healthy people through various methods and then transplant it into patients and used to treat various diseases.
- Dec 2021Series B$100M
- Dec 2020Series B—
- Nov 2019Series B—
- Jun 2019Series A—
#4
Series B · Shenzhen, Guangdong Province · founded 2015 · 500 employees$100Mraised▾
CDMO focused on manufacturing of APIs
- Aug 2021Series B$100M
#5
Seed · Shenzhen, Guangdong · founded 2021$14.8Mraised▾
Supplier and wholesaler of bio-pharmaceutical products. The company mainly focuses on the development of bio-based materials and related medical care and products based on synthetic biology and machine learning dual-core technology, providing customers with safe and reliable sustainable solutions.
- Jan 2023Seed$14.8M
#6
Seed · Shenzhen, Guangdong Province · founded 2020$13.9Mraised▾
Provider of upstream sequencing platforms development services
#7
Public · Shenzhen, Guangdong Province · founded 2014 · 970 employees$82.9Mraised▾
Operator of medical imaging centers providing diagnostic and related healthcare services. The organization focuses on delivering imaging services through a network of facilities. Core services encompass imaging center operations, solutions for medical imaging, and cloud-based services. It also conducts research and development in relevant areas and offers specialized services.
- Jul 2019Series C—
- Sep 2018Series B$18.9M
- Feb 2018Series B$64M
- 2016Series A—
#8
Series B · Shenzhen, Guangdong Province · founded 2008$56.5Mraised▾
Manufacturer of blood pressure measurement and laser therapy devices
#9
Series B · Shenzhen, Guangdong Province · founded 2016 · 19 employees$6.2Mraised▾
Manufacturer of medical disposables & devices, and wearable medical products
- Feb 2023Series B—
- Jul 2021Series A$6.2M
#10
Series B · Shenzhen, Guangdong Province · founded 2017 · 127 employees$28.3Mraised▾
Developer of addiction treatment drugs intended to prevent opioid drug users from relapse. The company focuses on the core technology of sustained and controlled drug addiction treatment, and the naltrexone sustained-release agent developed has completed phase II clinical trials. Naltrexone is the only opioid anti-relapse drug recommended by WHO. The company has developed naltrexone sustained-release agent through subcutaneous implantation to release the drug slowly and evenly, effectively solving the industry's pain points of relapse of opioids.
- Aug 2021Series B$28.3M
#11
Series B · Shenzhen, Guangdong Province · founded 2016$15.5Mraised▾
Manufacturer of flow cytometer, sampling tray, lysing, and other lab tools
- Jul 2021Series B$15.5M
#12
Series B · Shenzhen, Guangdong Province · founded 2016 · 130 employees$15.5Mraised▾
Provider of bio-technology platform to harness the prolific bio-fuel yield from micro-algae. The company provides a platform to cultivate microalgae and cyano-bacteria in order to harness the prolific products including hydrocarbon-based biofuel, feedstock and high-value byproduct.
- May 2021Series B$15.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.